Classics in chemical neuroscience: Clozapine

ACS Chemical Neuroscience

Volumn 4, Issue 7, 2013, Pages 1018-1025

  Wenthur, Cody J ^a   Lindsley, Craig W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

clozapine; N desmethylclozapine; pharmacology; schizophrenia

Indexed keywords

CLOZAPINE;

ADRENERGIC ACTIVITY; AGRANULOCYTOSIS; BONE MARROW SUPPRESSION; CHEMICAL NEUROSCIENCE; CHOLINERGIC ACTIVITY; CONSTIPATION; DROWSINESS; DRUG EFFICACY; DRUG INFORMATION; DRUG MANUFACTURE; DRUG METABOLISM; DRUG RECALL; DRUG STRUCTURE; DRUG SYNTHESIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSALIVATION; HYPERTRANSAMINASEMIA; HYPOTENSION; MYOCARDITIS; NEUROSCIENCE; NEUROTRANSMISSION; POLYMERIZATION; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOSIS; RESPIRATORY TRACT DISEASE; REVIEW; SCHIZOPHRENIA; SEIZURE; SEROTONINERGIC SYSTEM; SIDE EFFECT; TREATMENT DURATION; URINE INCONTINENCE; VERTIGO; WITHDRAWAL SYNDROME;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84880362714     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400121z     Document Type: Review

References (60)

1. Weinberger, D. R. and Harrison, P. J., Eds., (2011) Schizophrenia, 3 rd ed., Wiley-Blackwell Publishing, Ltd., Oxford, UK.
2. Carlsson, A. and Lindquist, M. (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normethanephrine in mouse brain Acta Pharmacol. Toxicol. 20, 140-144
3. Andreasen, N. C. (2000) Schizophrenia: the fundamental questions Brain Res. Rev. 31, 106-112
4. Karayiorgou, M. (2001) Genetic aspects of schizophrenia Clin. Neurosci. Res. 1, 158-163
5. Seeman, P., Lee, T., Chau-Wong, M., and Wong, K. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors Nature 261, 717-719
6. Seeman, P. and Lee, T. (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons Science 188, 1217-1219
7. Burns, M. J. (2001) The pharmacology and toxicology of atypical antipsychotic agents Clin. Toxicol. 39, 1-14
8. Breier, A., Buchanan, R. W., Kirkpatrick, B., David, O. R., Irish, D., Summerfelt, A., and Carpenter, J. W., Jr. (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia Am. J. Psychiatry 151, 20-26
9. Kane, J., Honigfeld, G., Singer, J., and Meltzer, H. Y. (1988) Clorazil Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine Arch. Gen. Psychiatry 45, 789-796
10. Buchanan, R. W., Breier, A., Kirkpatrick, B., Ball, P., and Carpenter, J. W., Jr. (1988) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome Am. J. Psychiatry 151, 755-760
11. Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., and Sheitman, B. (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials Am. J. Psychiatry 158, 518-526
12. Meltzer, H. Y. (1997) Treatment-resistant schizophrenia-The role of clozapine Curr. Med. Res. Opin. 14, 1-20
13. Naheed, M. and Green, B. (2001) Focus on clozapine Curr. Med. Res. Opin. 17, 223-229
14. Fakra, E. and Azorin, J.-M. (2012) Clozapine for the treatment of schizophrenia Expert Opin. Pharmacother. 13, 1923-1935
15. Meltzer, H. Y. and Stahl, S. M. (1976) The dopamine hypothesis of schizophrenia: a review Schizophr. Bull. 2, 19-76
16. Creese, I., Burr, D. R., and Synder, S. H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 19, 481-483
17. Coward, D. M. (1992) General pharmacology of clozapine Br. J. Psychiatry 160, 5-11
18. Kapur, S. and Seeman, P. (2000) Does fast dissociation from the dopamine (d2) receptor explain the action of atypical antipsychotics? A new hypothesis Am. J. Psychiatry 57, 553-559
19. i values J. Pharmacol. Exp. Ther. 251, 238-246
20. Janssen, P. A., Niemegeers, C. J., Awouters, F., Schellenkens, K. H., Megens, A. A., and Meert, T. F. (1988) Pharmaoclgoy of risperidone (R 64776), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonisitc properties J. Pharmacol. Exp. Ther. 244, 685-693
21. Olney, J. W., Newcomer, J. W., and Farber, N. B. (1999) NMDA receptor hypofunction model of schizophrenia J. Psychiatr. Res. 33, 523-533
22. Lindsley, C. W., Shipe, W. D., Wolkenberg, S. E., Theberge, C. R., Williams, D. L., Jr., Sur, C., and Kinney, G. G. (2006) Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia Curr. Top. Med. Chem. 8, 771-784
23. Menniti, F. S., Lindsley, C. W., Conn, P. J., Pandit, J., Zagouras, P., and Volkmann, R. A. (2013) Allosteric modulation for the treatment of schizophrenia: Targeting glutamatergic networks Curr. Top. Med. Chem. 13, 26-54
24. Moghaddam, B. and Javitt, D. (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implications for treatment Neuropsychopharmacol. Rev. 37, 4-15
25. Conn, P. J., Tamminga, C., Schoepp, D. D., and Lindsley, C. (2008) Schizophrenia: Moving Beyond Monoamine Antagonists Mol. Interventions 8, 99-105
26. Javitt, D. C., Duncan, L., Balla, A., and Sershen, H. (2005) Inhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanism of action Mol. Psychiatry 10, 276-286
27. Marino, M. J., Rouse, S. T., Levey, A. I., and Potter, L. T. (1998) Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells Proc. Natl. Acad. Sci. U.S.A. 95, 11465-11470
28. Sur, C., Mallorga, P. J., Wittman, M., Jacobson, M. A., Pascarella, D., Williams, J. B., Brandish, P. E., Pettibone, D. J., Scolnick, E. M., and Conn, P. J. (2003) N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity Proc. Natl. Acad. Sci. U.S.A. 100, 13674-13679
29. Li, Z., Huang, M., Ichikawa, J., Dai, J., and Meltzer, H. Y. (2005) N -Desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors Neuropsychopharmacology 30, 1986-1995
30. Marino, P. J. and Conn, P. J. (2002) Direct and indirect modulation of the N -methyl- d -Aspartate receptor: potential for the development of novel antipsychotic therapies Curr. Drug Targets: CNS Neurol. Disord. 1, 1-16
31. Bridges, T. M., LeBois, E. P., Hopkins, C. R., Wood, M. R., Jones, J. K., Conn, P. J., and Lindsley, C. W. (2010) Antipsychotic potential of muscarinic allosteric modulation Drug News Perspect. 23, 229-240
32. Shannon, H. E., Rasmussen, K., Bymaster, F. P., Hart, J. C., Peters, S. C., Swedberg, M. D., Jeppesen, L., Sheardown, M. J., Sauerberg, P., and Fink-Jensen, A. (2000) Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice Schizophr. Res. 42, 249-259
33. Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dube, S., Mallinckrodt, C., Bymaster, F. P., McKinzie, D. L., and Felder, C. C. (2008) Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia Am. J. Psychiatry 165, 1033-1039
34. "Supplimental NDA Approval Letter for Clozaril, NDA 19-758/S-047". United States Food and Drug Administration. December 18, 2002. Archived from the original on June 3, 2013.
35. Cohen, D., Bogers, J. P., van Dijk, D., Bakker, B., and Schulte, P. F. (2012) Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy J. Clin. Psychiatry 73, 1307-1310
36. Schmutz, J. and Hunziker, F. (1970) 11-Basic substituted dibenzodiazepines and dibenzothiazepines. US 3,539,573.
37. Hunziker, F., Fischer, E., and Schmutz, J. (1967) 11-Amino-5 H -dibenzo[ b, e ]-1,4-diazepine Helv. Chim. Acta 50, 1588-1599
38. Liao, Y., Venhuis, B. J., Rodenhuis, N., Timmerman, W., and Wikstrom, H. (1999) New (sulfonyloxy)piperazinylbibenzadiazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation J. Med. Chem. 42, 2235-2244
39. de Paulis, T., Davis, D. A., and Smith, H. E. (1988) Synthesis of [3H]clozapine J. Labeled Comp. Pharm. 25, 1027-1033
40. For information on clozapine (clorazil), see www.Novartis.com.
41. For information on clozapine (clorazil), see www.clorazil.com
42. Sikora, A., Adamus, J., and Marcinek, A. (2007) Disproportionation of clozapine radical: A link between one-electron oxidation and formation of it nitrenium cation Chem. Res. Toxicol. 20, 1093-1098
43. Dragovic, S., Boerma, J. S., van Bergen, L., Vermeulen, N. P. E., and Commandeur, J. N. M. (2010) Role of glutathione S-transferase in the inactivation of reactive metabolites of clozapine Chem. Res. Toxicol. 23, 1467-1476
44. Gardener, I., Popovic, M., Zahid, N., and Uetrecht, J. P. (2005) A comparison of the covalent binding of clozapine, procainamide and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo Chem. Res. Toxicol. 18, 1384-1394
45. Dain, J. G., Nicoletti, J., and Ballard, F. (1997) Biotransformations of clozapine in humans Drug Metab. Dispos. 25, 603-609
46. Wiebelhaus, J. M., Vunck, S. A., Meltzer, H. Y., and Porter, J. H. (2012) Discriminative stimulus properties of N -desmethylclozapine, the major active metabolite of the atypical antipsychotic clozapine, in C57BL/6 mice Behav. Pharmacol. 23, 262-270
47. Cremers, T. I. F., Flik, G., Hofland, C., and Stratford, R. E., Jr. (2012) Microdialysis evaluation of clozapine and N -desmethylclozapine pharmacokinetics in rat brain Drug Metab. Dispos. 40, 1909-1916
48. 1A receptors Eur. J. Pharmacol. 669, 51-58
49. Maehara, S., Okuda, S., and Ohta, H. (2011) Ameliorative effect of N -desmethylclozapine in animal models of social deficits and cognitive functions Brain Res. Bull. 86, 146-151
50. 4 receptors Neuropsychopharmaoclogy 16, 93-110
51. Meltzer, H. Y. (1999) The role of serotonin in antipsychotic drug action Neuropsychopharmaoclogy 21, 106S-115S
52. Natesan, S., Reckless, G. E., Barlow, K. B. L., Nobrega, J. N., and Kapur, S. (2007) Evaluation of N -desmethylclozapine as a potential antipsychotic-preclinical studies Neuropsychopharmaoclogy 32, 1540-1549
53. 1 receptor Neuropharmacology 58, 1206-1214
54. 1 receptor function ACS Chem. Neurosci. 1, 104-121
55. 1 muscarinic acetylcholine receptor induce brain region-specific responses and correspond with behavioral effects in animal models J. Neurosci. 32, 8532-8544
56. 1 agonist VU0364572 reveals molecular switches in pharmacology as well as a bitopic binding mode ACS Chem. Neurosci. 3, 1025-1036
57. Flanagan, R. J. (2008) Sides effects of clozapine and some other psychoactive drugs Curr. Drug Saf. 3, 115-122
58. Burns, M. J. (2001) The pharmacology and toxicology of atypical antipsychotic agents Clin. Toxicol. 39, 1-14
59. Meltzer, H. Y. and Cola, P. A. (1994) The pharmacoecomonics of clozapine: a review J. Clin. Psychiatry 55 (Suppl. B) 161-165
60. Kelly, D. L. and Buchanan, R. W. (2007) Why not clozapine? Clin. Schizophr. Relat. Psychoses 1, 92-95-95